| scholarly article | Q13442814 |
| P50 | author | Ana Lluch | Q67755317 |
| P2093 | author name string | Ana Rovira | |
| Joan Albanell | |||
| Sandra Zazo | |||
| Federico Rojo | |||
| Silvia Menéndez | |||
| Octavio Burgués | |||
| Pilar Eroles | |||
| Juan Madoz-Gúrpide | |||
| Elisa Alonso | |||
| Begoña Bermejo | |||
| Eduardo Tormo | |||
| Sandra Ballester | |||
| Anna Adam-Artigues | |||
| P2860 | cites work | miR-449 inhibits cell proliferation and is down-regulated in gastric cancer | Q21245766 |
| Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents | Q27027060 | ||
| The functions of animal microRNAs | Q27860621 | ||
| Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1 | Q28145116 | ||
| Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle | Q28189224 | ||
| The emerging role of E2F-1 in the DNA damage response and checkpoint control | Q28274309 | ||
| Involvement of the CDK2-E2F1 pathway in cisplatin cytotoxicity in vitro and in vivo. | Q50469558 | ||
| The microRNA-449 family inhibits TGF-β-mediated liver cancer cell migration by targeting SOX4. | Q50952919 | ||
| Directed therapy of subtypes of triple-negative breast cancer. | Q54614594 | ||
| Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer | Q78222751 | ||
| miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients | Q31136911 | ||
| Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres | Q33370714 | ||
| Control of the cell cycle and apoptosis | Q33735440 | ||
| Triple-negative breast cancer: clinical features and patterns of recurrence | Q34658655 | ||
| Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. | Q34798833 | ||
| E2F1-inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis | Q35015916 | ||
| MiR-449a suppresses the epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma by multiple targets | Q35809301 | ||
| DIANA-miRPath v3.0: deciphering microRNA function with experimental support | Q35810103 | ||
| Mechanisms of translational control by the 3' UTR in development and differentiation | Q36013975 | ||
| Conserved functions of the pRB and E2F families | Q37249375 | ||
| MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer | Q37388413 | ||
| miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. | Q37393628 | ||
| AMP-activated protein kinase α2 and E2F1 transcription factor mediate doxorubicin-induced cytotoxicity by forming a positive signal loop in mouse embryonic fibroblasts and non-carcinoma cells | Q37596326 | ||
| Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-кB target genes in human breast cancer | Q37649660 | ||
| Management of triple negative breast cancer | Q37728718 | ||
| MiRNA-34 intrinsically links p53 tumor suppressor and Wnt signaling. | Q37993984 | ||
| Adjuvant treatments for triple-negative breast cancers | Q38046581 | ||
| Triple-negative breast cancer: epidemiological considerations and recommendations | Q38046586 | ||
| miR-449a inhibits proliferation and invasion by regulating ADAM10 in hepatocellular carcinoma | Q38758912 | ||
| MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer | Q38895915 | ||
| MiR-449a exerts tumor-suppressive functions in human glioblastoma by targeting Myc-associated zinc-finger protein | Q38930784 | ||
| MiR-449a functions as a tumor suppressor in endometrial cancer by targeting CDC25A. | Q38978290 | ||
| miR-449a Regulates proliferation and chemosensitivity to cisplatin by targeting cyclin D1 and BCL2 in SGC7901 cells | Q39061607 | ||
| MicroRNAs-449a and -449b exhibit tumor suppressive effects in retinoblastoma | Q39080202 | ||
| Doxorubicin induces the DNA damage response in cultured human mesenchymal stem cells. | Q39257323 | ||
| Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells. | Q39352451 | ||
| Combining microRNA-449a/b with a HDAC inhibitor has a synergistic effect on growth arrest in lung cancer. | Q39444162 | ||
| MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy | Q39880558 | ||
| The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays | Q40240269 | ||
| E2F1 is crucial for E2F-dependent apoptosis | Q43167748 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | doxorubicin | Q18936 |
| triple-negative breast cancer | Q7843332 | ||
| P304 | page(s) | 5316 | |
| P577 | publication date | 2019-03-29 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors | |
| P478 | volume | 9 |
| Q89537417 | A Chemotherapy-Driven Increase in Mcl-1 Mediates the Effect of miR-375 on Cisplatin Resistance in Osteosarcoma Cells |
| Q92826406 | Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge |
| Q89989669 | MicroRNA‑449a regulates the progression of brain aging by targeting SCN2B in SAMP8 mice |
| Q92211767 | miR-29b-3p promotes progression of MDA-MB-231 triple-negative breast cancer cells through downregulating TRAF3 |
| Q89720471 | microRNAs Orchestrate Pathophysiology of Breast Cancer Brain Metastasis: Advances in Therapy |
Search more.